|
|
|
|
|
|
|
28.10.26 - 12:18
|
Boston Scientific Corp Q3 Profit Declines (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Boston Scientific Corp (BSX) released earnings for third quarter that Drops, from last yearThe company's earnings came in at $582 million, or $0.40 per share. This compares ......
|
|
|
|
|
|
|
28.10.26 - 11:33
|
Boston Scientific announces results for third quarter 2026 (PR Newswire)
|
|
|
MARLBOROUGH, Mass., Oct. 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operational1 and organic2 basis, all compared to the prior year period. The company......
|
|
|
|
|
|
|
|
|
|
|
20.10.26 - 22:06
|
Vertex Appoints Daniel Brennan to its Board of Directors (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific's Executive Vice President, Chief Financial Officer, where he had responsibility for all global finance functions and corporate business development.
“Dan's extensive financial leadership experience and deep understanding of global healthcare businesses will bring an important perspective to the Vertex Board,” said Jeffrey Leiden, M.D., Ph.D., Executive Chairman of Vertex. “His experience navigating periods of high growth and strategic expansion will be especially valuable as Vertex continues to expand, diversify and invest in innovation so we...
|
|
|
|
|
|
|
|
|
07.10.26 - 16:54
|
Boston Scientific Aktie: Medtech-Sektor vor der Erholung? (Aktiencheck)
|
|
|
London (www.aktiencheck.de) - Boston Scientific-Aktienanalyse von Barclays:
Barclays habe die Coverage der Aktie von Boston Scientific Corp. (ISIN: US1011371077, WKN: 884113, Ticker-Symbol: BSX, NYSE-Symbol: BSX) mit dem Rating "equal weight" und einem Kursziel von 48 USD aufgenommen. Gleichzeitig habe die Bank die Coverage für den gesamten Bereich der Medizintechnik- und Medizinprodukteunternehmen mit einer positiven Sektoreinschätzung gestartet. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
